Literature DB >> 16399737

Medical treatment of early breast cancer. I: adjuvant treatment.

Ian Smith1, Susan Chua.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16399737      PMCID： PMC1325133          DOI： 10.1136/bmj.332.7532.34

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.

Authors:  W Eiermann; S Paepke; J Appfelstaedt; A Llombart-Cussac; J Eremin; J Vinholes; L Mauriac; M Ellis; M Lassus; H A Chaudri-Ross; M Dugan; M Borgs
Journal:  Ann Oncol       Date:  2001-11       Impact factor: 32.976

2.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

Authors:  A Goldhirsch; J H Glick; R D Gelber; A S Coates; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2005-09-07       Impact factor: 32.976

3.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

4.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

Authors:  B Fisher; J Bryant; N Wolmark; E Mamounas; A Brown; E R Fisher; D L Wickerham; M Begovic; A DeCillis; A Robidoux; R G Margolese; A B Cruz; J L Hoehn; A W Lees; N V Dimitrov; H D Bear
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

Review 5.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Authors:  Eric P Winer; Clifford Hudis; Harold J Burstein; Antonio C Wolff; Kathleen I Pritchard; James N Ingle; Rowan T Chlebowski; Richard Gelber; Stephan B Edge; Julie Gralow; Melody A Cobleigh; Eleftherios P Mamounas; Lori J Goldstein; Timothy J Whelan; Trevor J Powles; John Bryant; Cheryl Perkins; Judy Perotti; Susan Braun; Amy S Langer; George P Browman; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544
  5 in total
  4 in total

1.  Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more.

Authors:  Keiichi Kontani; Shin-Ichiro Hashimoto; Chisa Murazawa; Shoko Norimura; Hiroaki Tanaka; Masahiro Ohtani; Naomi Fujiwara-Honjo; Manabu Date; Hitoshi Houchi; Hiroyasu Yokomise
Journal:  Mol Clin Oncol       Date:  2012-12-10

2.  Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I-II breast cancers.

Authors:  A V Tinker; C Speers; J Barnett; I A Olivotto; S Chia
Journal:  Ecancermedicalscience       Date:  2008-07-08

3.  Factors responsible for long-term survival in metastatic breast cancer.

Authors:  Keiichi Kontani; Shin-ichiro Hashimoto; Chisa Murazawa; Shoko Norimura; Hiroaki Tanaka; Masahiro Ohtani; Naomi Fujiwara-Honjo; Manabu Date; Koji Teramoto; Hitoshi Houchi; Hiroyasu Yokomise
Journal:  World J Surg Oncol       Date:  2014-11-14       Impact factor: 2.754

4.  Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance.

Authors:  Derek W Edwardson; Justin Boudreau; Jonathan Mapletoft; Carita Lanner; A Thomas Kovala; Amadeo M Parissenti
Journal:  PLoS One       Date:  2017-09-15       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.